Department of First Clinical Medical College, Zhejiang Chinese Medical University, 310000, China.
The Third Affiliated Hospital of Beijing University of Chinese Medicine, No. 51 Anwai Xiaoguanjie, Chaoyang District, Beijing 100029, China.
Biomed Pharmacother. 2022 Dec;156:113790. doi: 10.1016/j.biopha.2022.113790. Epub 2022 Oct 13.
Tumor-derived extracellular vesicles (EVs) are key immune regulators of the tumor microenvironment. They reshape the immune microenvironment and prevent antitumor immune responses via their immunosuppressive cargo, thereby determining cancer responsiveness to treatment. In the immune microenvironment of melanoma, tumor-derived EVs influence tumor progression by regulating innate and adaptive immune responses. Tumor-derived EV-based therapy is a cutting-edge and promising strategy for inhibiting melanoma progression and enhancing antitumor immunity. This review aimed to summarize the regulatory roles of EVs in the immune responses and immunotherapy of patients with melanoma. This paper provided insights into future exploration directions and potential clinical strategies targeting EVs for melanoma treatment.
肿瘤来源的细胞外囊泡(EVs)是肿瘤微环境中关键的免疫调节因子。它们通过免疫抑制性 cargo 重塑免疫微环境并阻止抗肿瘤免疫反应,从而决定癌症对治疗的反应性。在黑色素瘤的免疫微环境中,肿瘤来源的 EV 通过调节先天和适应性免疫反应影响肿瘤进展。基于肿瘤来源的 EV 的治疗是抑制黑色素瘤进展和增强抗肿瘤免疫的一种前沿且有前途的策略。本综述旨在总结 EV 在黑色素瘤患者的免疫反应和免疫治疗中的调节作用。本文为针对黑色素瘤治疗的 EV 靶向未来探索方向和潜在临床策略提供了思路。